Site-independent confirmation of subject selection for CNS trials: 'dual' review using audio-digital recordings

Annals of General Psychiatry

Volumn 13, Issue 1, 2014, Pages

  Targum, Steven D ^a   Pendergrass, J C ^a  

^a Clintara LLC   (United States)

Author keywords

Clinical trials; Drug development; Rater competency; Site independent review; Subject selection; Subject validity; Surveillance: audio digital recording

Indexed keywords

PLACEBO;

ALZHEIMER DISEASE; ARTICLE; AUDIO DIGITAL RECORDING; AUDIO RECORDING; CLINICAL VALIDATION INVENTORY FOR STUDY ADMISSION; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DOCUMENTATION; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); RECORDING; SCHIZOPHRENIA; TELEPHONE; TELEPHONE INTERVIEW;

EID: 84908372750     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/s12991-014-0021-3     Document Type: Article

References (43)

1. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial and growing. JAMA 2002, 287:1840-1847. 10.1001/jama.287.14.1840, 11939870.
2. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the U.S. Food and Drug Administration in support of new drug applications. J Clin Psychiatry 2011, 72(4):464-472. 10.4088/JCP.10m06191, 21527123.
3. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration Database. J Clin Psychopharmacology 2002, 22:40-45. 10.1097/00004714-200202000-00007.
4. Khan A, Kolts RL, Rapaport MH, Krishnan KRR, Brodhead AE, Brown WA. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med 2005, 35:743-749. 10.1017/S0033291704003873, 15918351.
5. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009, 19:34-40. 10.1016/j.euroneuro.2008.08.009, 18823760.
6. Fava M, Evins A, Dorer D, Schoenfeld D. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003, 72(3):115-127. 10.1159/000069738, 12707478.
7. Kemp AS, Scholler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dubé S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?. Proceedings of the First Collaborative Session between the ISCTM and the ISCDD 2008, 2007. Schizophrenia Bulletin, Brussels, Belgium.
8. Kobak KA, Feiger AD, Lipsitz JD. Interview quality and signal detection in clinical trials. Am J Psychiatry 2004, 162:628. 10.1176/appi.ajp.162.3.628.
9. Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms?. J Clin Psychopharmacol 2007, 27(1):1-5. 10.1097/JCP.0b013e31802eb4b7, 17224705.
10. Targum SD. Evaluating rater competency for CNS clinical trials. J Clin Psychopharm 2006, 26(3):308-310. 10.1097/01.jcp.0000219049.33008.b7.
11. Targum SD, Pollack MH, Fava M. Re-defining affective disorders: relevance for drug development. CNS Neurosci Ther 2008, 14:2-9. 10.1111/j.1755-5949.2008.00038.x, 18482094.
12. Targum SD, Houser C, Northcutt J, Little LA, Cutler AJ, Walling DP. A structured interview guide for global impressions: reliability and validity for CNS trials. Ann Gen Psychiat 2013, 12:2-6. 10.1186/1744-859X-12-2.
13. Leon AC, Marzak PM. More reliable outcome measures can reduce sample size requirements. Arch Gen Psychiatry 1995, 52:867-871. 10.1001/archpsyc.1995.03950220077014, 7575107.
14. Perkins DO, Wyatt RJ, Bartko JJ. Penny wise and dollar foolish: the impact of measurement error on sample size requirements in clinical trials. Biol Psychiat 2000, 47:762-766. 10.1016/S0006-3223(00)00837-4, 10773186.
15. Muller MJ, Szegedi A. Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials. J Clin Psychopharmacol 2002, 22:318-325. 10.1097/00004714-200206000-00013, 12006903.
16. DeBrota DJ, Demitrack MA, Landin R, Kobak KA, Greist JH, Potter WZ. A comparison between interactive voice response system-administered HAM-D and clinician- administered HAM-D in patients with major depressive episode 1999, 39th Annual NCDEU Meeting, Boca Raton, FL.
17. Feltner DE, Kobak KA, Crockatt J, Haber H, Kavoussi R, Pande A, Greist JH. Interactive voice response (IVR) for patient screening of anxiety in a clinical drug trial 2001, 41st Annual NCDEU Meeting, Phoenix, AZ.
18. Dunn J. Comparison of site-based versus centralized ratings in a study of generalized anxiety disorder 2010, 163rd Annual APA meeting, New Orleans, LA.
19. Chandler G, Targum SD, Pollack M, Iosifescu D, Mischoulon D, Perlis R, Witte J, Fava M. Validation of patients for a CNS trial of major depressive disorder 2009, 49th Annual NCDEU meeting, Hollywood, FL.
20. Schoemaker J, Gaur R, Chawla V, Jansen W, Szegedi A. Expert rater assisted score evaluation (ERASE): a new method to enhance signal detection in randomized, placebo-controlled clinical trials 2009, 49th Annual NCDEU, Hollywood, FL.
21. Glaudin V, Smith WT, Ferguson JM, DuBoff EA, Rosenthal MH, Mee-Lee D. Discriminating placebo and drug in generalized anxiety disorder (GAD) trials: single vs. multiple raters. Psychopharmacol Bull 1994, 32:175-178.
22. Simon GE, Revicki D, VonKorff M. Telephone assessment of depression severity. J Psychiat Res 1993, 27(3):247-252. 10.1016/0022-3956(93)90035-Z, 8295157.
23. Rohde P, Lewinsohn PM, Seeley JR. Comparability of telephone and face-to-face interviews in assessing axis I and II disorders. Am J Psychiatr 1997, 154:1593-1598. 9356570.
24. Kobak KA, Leuchter A, DeBrota D, Engelhardt N, Williams JBW, Cook I, Leon A, Alpert J. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol 2010, 30(2):193-197. 10.1097/JCP.0b013e3181d20912, 20520295.
25. Moore HK, Wohlreich MM, Wilson MG, Mundt JC, Fava M, Mallincrodt CH, Greist JH. Using daily interactive voice response assessments to measure onset of symptom improvement with duloxetine. Psychiatry 2007, 4(3):30-38. 20805908.
26. Shen J, Kobak KA, Zhao Y, Alexander M, Kane J. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. J Clin Psychopharmacol 2008, 28(6):691-693. 10.1097/JCP.0b013e31818c9ba3, 19011439.
27. Kendell R, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiat 2003, 160(1):4-12. Am J Psychiat., 126: 983-987, 10.1176/appi.ajp.160.1.4, 12505793.
28. Regier DA, Kaelber CT, Rae DS, Farmer ME, Knauper B, Kessler RC, Norquist GS. Limitations of diagnostic and assessment instruments for mental disorders. Arch Gen Psychiat 1998, 55:109-115. 10.1001/archpsyc.55.2.109, 9477922.
29. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical interview for DSM-IV Axis I Disorders (SCID) 1995, Biometric Research Department, New York Psychiatric Institute.
30. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(20):22-33. 9881538.
31. Targum SD, Little JA, Lopez E, DeMartinis N, Rapaport M, Ereshefsky L. Application of external review for subject selection in a schizophrenia trial. J Clin Psychopharmacol 2012, 32(2):825-826. 10.1097/JCP.0b013e318248da90, 22388170.
32. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987, 13:261-276. 10.1093/schbul/13.2.261.
33. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988, 24:97-99.
34. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician J Psychiatric Res 1975, 12(3):189-198.
35. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Brit J Psychiat 1982, 140:566-572. 10.1192/bjp.140.6.566, 7104545.
36. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984, 141(11):1356-1364. 6496779.
37. Gaur R, Ramirez L, De Santi S, Schoemaker J. Rater training on SANS and monitoring of rater performance during clinical trials. ISCTM 5th Annual meeting 2009,
38. Leigh-Pemberton R, Memisglo A, Targum S, Pendergrass C, Rauh P, Marshall R, Silverman B, de Somer M, Ehrich E. Blinded dual ratings confirm primary site-based ratings in an MDD trial 2014, Annual ASCP Meeting, Hollywood, FL.
39. Asgharnejad M, Targum S, Burch D, Gibertini M, Fava M. Surveillance strategies to improve study outcomes in a depression study 2012, 52nd Annual NCDEU meeting, Boca Raton, FL.
40. Keller WR, Bernard A, Fischer BA, Carpenter WT. Revisiting the diagnosis of schizophrenia: where have we been and where are we going?. CNS Neurosci Ther 2011, 17:83-88. 10.1111/j.1755-5949.2010.00229.x, 21199450.
41. Kendler KS, Gardner CO. Boundaries of major depression: an evaluation of DSM-IV criteria. Am J Psychiat 1998, 155:172-177. 9464194.
42. Lambert MJ. Handbook of psychotherapy integration 1992, Basic Books, New York.
43. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention and Treatment 1998, 1(2):Article 0002a. doi: 10.1037/1522-3736.1.1.12a.